TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 288 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2021. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $18,000 | -10.0% | 1,291 | -9.3% | 0.00% | 0.0% |
| Q1 2022 | $20,000 | +400.0% | 1,424 | +376.3% | 0.00% | +300.0% |
| Q4 2021 | $4,000 | -85.7% | 299 | -82.5% | 0.00% | -80.0% |
| Q3 2021 | $28,000 | +3.7% | 1,707 | +5.0% | 0.01% | 0.0% |
| Q2 2021 | $27,000 | -18.2% | 1,625 | -10.9% | 0.01% | -37.5% |
| Q1 2021 | $33,000 | -57.1% | 1,823 | -57.0% | 0.01% | -57.9% |
| Q4 2020 | $77,000 | +185.2% | 4,240 | +181.4% | 0.02% | +111.1% |
| Q3 2020 | $27,000 | 0.0% | 1,507 | 0.0% | 0.01% | -10.0% |
| Q2 2020 | $27,000 | +68.8% | 1,507 | +41.8% | 0.01% | +42.9% |
| Q1 2020 | $16,000 | +77.8% | 1,063 | +135.2% | 0.01% | +133.3% |
| Q4 2019 | $9,000 | +12.5% | 452 | 0.0% | 0.00% | -25.0% |
| Q3 2019 | $8,000 | +14.3% | 452 | +8.7% | 0.00% | +33.3% |
| Q2 2019 | $7,000 | 0.0% | 416 | +25.7% | 0.00% | -25.0% |
| Q1 2019 | $7,000 | – | 331 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Glenview Capital Management | 16,104,222 | $294,063,000 | 4.98% |
| GMT CAPITAL CORP | 2,468,695 | $45,078,000 | 3.31% |
| MANAGED ASSET PORTFOLIOS, LLC | 1,065,756 | $19,461,000 | 3.13% |
| Blackcrane Capital, LLC | 14,571 | $1,723,000 | 2.72% |
| BFAM Partners (Cayman) Ltd | 328,690 | $6,002,000 | 2.36% |
| Paulson & Co. | 4,727,415 | $86,323,000 | 1.98% |
| Mondrian Investment Partners LTD | 3,510,404 | $59,677,000 | 1.28% |
| Lumbard & Kellner, LLC | 135,550 | $2,264,000 | 0.80% |
| DAVIDSON INVESTMENT ADVISORS | 500,203 | $9,134,000 | 0.78% |
| TFG Asset Management GP Ltd | 589,390 | $10,762,000 | 0.77% |